BRPI0816712A2 - terapia de intervalo para o tratamento de tinnitus - Google Patents

terapia de intervalo para o tratamento de tinnitus

Info

Publication number
BRPI0816712A2
BRPI0816712A2 BRPI0816712A BRPI0816712A BRPI0816712A2 BR PI0816712 A2 BRPI0816712 A2 BR PI0816712A2 BR PI0816712 A BRPI0816712 A BR PI0816712A BR PI0816712 A BRPI0816712 A BR PI0816712A BR PI0816712 A2 BRPI0816712 A2 BR PI0816712A2
Authority
BR
Brazil
Prior art keywords
tinnitus
treatment
interval therapy
therapy
interval
Prior art date
Application number
BRPI0816712A
Other languages
English (en)
Inventor
Barbara Ellers-Lenz
Hagen Krueger
Hermann Russ
Michael Althaus
Tanja Rosenberg
Original Assignee
Merz Pharma Gmbh & Co Kgaa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merz Pharma Gmbh & Co Kgaa filed Critical Merz Pharma Gmbh & Co Kgaa
Publication of BRPI0816712A2 publication Critical patent/BRPI0816712A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Otolaryngology (AREA)
  • Neurosurgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medical Preparation Storing Or Oral Administration Devices (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Percussion Or Vibration Massage (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
BRPI0816712A 2007-09-12 2008-09-10 terapia de intervalo para o tratamento de tinnitus BRPI0816712A2 (pt)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US99339607P 2007-09-12 2007-09-12
EP07253630 2007-09-12
US6708308P 2008-02-25 2008-02-25
US6702608P 2008-02-25 2008-02-25
US6693108P 2008-02-25 2008-02-25
EP08004778 2008-03-14
EP08004776 2008-03-14
EP08004777 2008-03-14
PCT/EP2008/007418 WO2009033649A1 (en) 2007-09-12 2008-09-10 Interval therapy for the treatment of tinnitus

Publications (1)

Publication Number Publication Date
BRPI0816712A2 true BRPI0816712A2 (pt) 2016-11-08

Family

ID=40451596

Family Applications (2)

Application Number Title Priority Date Filing Date
BRPI0816690A BRPI0816690A2 (pt) 2007-09-12 2008-09-10 derivados 1-amino-alquilciclohexano para tratamento e a prevenção da perda da audição
BRPI0816712A BRPI0816712A2 (pt) 2007-09-12 2008-09-10 terapia de intervalo para o tratamento de tinnitus

Family Applications Before (1)

Application Number Title Priority Date Filing Date
BRPI0816690A BRPI0816690A2 (pt) 2007-09-12 2008-09-10 derivados 1-amino-alquilciclohexano para tratamento e a prevenção da perda da audição

Country Status (21)

Country Link
US (6) US9468610B2 (pt)
EP (6) EP2548552B1 (pt)
JP (6) JP5563460B2 (pt)
KR (4) KR20100052556A (pt)
CN (4) CN101801366A (pt)
AR (3) AR070026A1 (pt)
AT (1) ATE532507T1 (pt)
AU (4) AU2008298016B2 (pt)
BR (2) BRPI0816690A2 (pt)
CA (4) CA2699213A1 (pt)
DK (1) DK2200600T3 (pt)
ES (5) ES2596262T3 (pt)
HR (1) HRP20120046T1 (pt)
MX (4) MX2010002735A (pt)
PL (1) PL2200600T3 (pt)
PT (1) PT2200600E (pt)
RU (1) RU2011137131A (pt)
SI (1) SI2200600T1 (pt)
TW (3) TW200927087A (pt)
WO (4) WO2009033651A1 (pt)
ZA (4) ZA201001262B (pt)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE532507T1 (de) * 2007-09-12 2011-11-15 Merz Pharma Gmbh & Co Kgaa Neramexane zur behandlung von subakuten tinnitus
US20110294890A1 (en) 2010-05-28 2011-12-01 Merz Pharma Gmbh & Co. Kgaa Neramexane for the treatment or prevention of inner ear disorders
EP2585049A1 (en) 2010-06-24 2013-05-01 Merz Pharma GmbH & Co. KGaA Neramexane multiple unit dosage form
JP6084931B2 (ja) * 2011-01-20 2017-02-22 メルツ ファーマ ゲゼルシャフト ミット ベシュレンクテル ハフツング ウント コンパニー コマンディト ゲゼルシャフト アウフ アクティーン ストレス又は急性聴力損失に関連する耳鳴の治療又は予防のためのネラメキサン
US20160129084A1 (en) * 2013-03-06 2016-05-12 Acorda Therapeutics, Inc. Therapeutic Dosing of a Neuregulin or a Fragment Thereof for Treatment or Prophylaxis of Heart Failure
JP5978472B2 (ja) * 2014-04-28 2016-08-24 杏林製薬株式会社 耳鳴患者の治療用の薬剤
CN106413698A (zh) * 2014-04-28 2017-02-15 杏林制药株式会社 耳鸣患者的治疗用药剂
MX394186B (es) 2014-10-23 2025-03-24 Arena Pharm Inc Metodo de tratamiento de afecciones relacionadas con el receptor pgi2
SMT202100459T1 (it) * 2015-05-18 2021-09-14 Sensorion Azasetron per l’uso nel trattamento della perdita dell’udito
KR101893604B1 (ko) 2015-08-27 2018-08-30 경희대학교 산학협력단 칸디다 유틸리스 추출물을 포함하는 난청의 예방 또는 치료용 조성물
CN105924362B (zh) * 2016-02-05 2018-08-17 上海龙翔生物医药开发有限公司 芳香环丙基胺类化合物、其药学上可接受的盐、其制备方法及其用途
EP3977985B1 (en) 2017-03-01 2023-09-06 Arena Pharmaceuticals, Inc. Compositions comprising pgi2-receptor agonists and processes for the preparation thereof
KR20210040837A (ko) 2018-05-16 2021-04-14 아레나 파마슈티칼스, 인크. Pgi2-수용체 효능제를 포함하는 조성물 및 그의 제조 방법
KR102268893B1 (ko) 2020-01-16 2021-06-24 경북대학교 산학협력단 림노트릭스 속 knua002 균주를 포함하는 난청의 예방 또는 치료용 조성물
CN111477199B (zh) * 2020-04-02 2021-11-30 北京瑞迪欧文化传播有限责任公司 一种嵌入式音乐控制系统
EP4297708A4 (en) 2021-09-09 2024-08-28 Samsung Electronics Co., Ltd. AUDIO CONTENT DELIVERY MANAGEMENT

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5811128A (en) 1986-10-24 1998-09-22 Southern Research Institute Method for oral or rectal delivery of microencapsulated vaccines and compositions therefor
US4849222A (en) 1987-03-24 1989-07-18 The Procter & Gamble Company Mixtures for treating hypercholesterolemia
JP2670680B2 (ja) 1988-02-24 1997-10-29 株式会社ビーエムジー 生理活性物質含有ポリ乳酸系微小球およびその製造法
US5288502A (en) 1991-10-16 1994-02-22 The University Of Texas System Preparation and uses of multi-phase microspheres
EP0724432B1 (en) 1993-10-22 2002-09-18 Genentech, Inc. Methods and compositions for microencapsulation of antigens for use as vaccines
DE19528388A1 (de) * 1995-08-02 1997-02-06 Hans Peter Prof Dr Med Zenner Verwendung von Adamantan-Derivaten zur Behandlung von Erkrankungen des Innenohrs
WO1998010757A2 (en) 1996-09-11 1998-03-19 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services The use of functional n-methyl-d-aspartate antagonists to ameliorate or prevent aminoglycoside-induced ototoxicity
US6071966A (en) 1997-06-30 2000-06-06 Merz + Co. Gmbh & Co. 1-amino-alkylcyclohexane NMDA receptor antagonists
UA61962C2 (uk) * 1997-06-30 2003-12-15 Мерц Фарма Гмбх Унд Ко. Кгаа Сполука 1-аміноалкілциклогексану, фармацевтична композиція на її основі та спосіб лікування
AU2001255620A1 (en) * 2000-04-26 2001-11-07 Warner-Lambert Company Cyclohexylamine derivative as subtype selective NMDA receptor antagonists
DE10048969A1 (de) * 2000-08-23 2002-03-14 Mueller Schwefe Gerhard Verwendung von Flupirtin zur Tinnitusbehandlung
US20030236288A1 (en) * 2002-02-28 2003-12-25 Karl Schoenafinger Use of substituted 3-phenyl-5-alkoxy-3H-(1,3,4)-oxadizol-2-ones for inhibiting pancreatic lipase
JP2004021734A (ja) 2002-06-18 2004-01-22 Nokia Corp キーパッドおよびキーパッドシステム
US7086532B2 (en) 2003-07-16 2006-08-08 Allergan, Inc. Titration/compliance pack with increasing doses
CA2497867A1 (en) * 2002-09-06 2004-03-18 Durect Corporation Delivery of modulators of glutamate-mediated neurotransmission to the inner ear
DE10252665A1 (de) * 2002-11-11 2004-06-03 Grünenthal GmbH 4-Aminomethyl-1-aryl-cyclohexylamin-Derivate
MXPA05012493A (es) 2003-05-27 2006-05-25 Forest Laboratories Combinacion de un antagonista del receptor de nmda y un inhibidor selectivo de reabsorcion de serotonina para el tratamiento de depresion y otros trastornos de estado de animo.
AR046314A1 (es) * 2003-11-05 2005-11-30 Merz Pharma Gmbh & Co Kgaa Composiciones que comprenden ciclohexilaminas y aminoadamantanos
US20060002999A1 (en) 2004-06-17 2006-01-05 Forest Laboratories, Inc. Immediate release formulations of 1-aminocyclohexane compounds, memantine and neramexane
ES2483126T3 (es) * 2004-06-17 2014-08-05 Merz Pharma Gmbh & Co. Kgaa Formulaciones de formas de dosificación de neramexano
US20060205822A1 (en) 2004-12-22 2006-09-14 Forest Laboratories, Inc. 1-Aminocyclohexane derivatives for the treatment of multiple sclerosis, emotional lability and pseudobulbar affect
WO2006079055A2 (en) * 2005-01-24 2006-07-27 Neurosystec Corporation Apparatus and method for delivering therapeutic and/or other agents to the inner ear and to other tissues
CN101163481A (zh) * 2005-03-04 2008-04-16 纽罗赛斯特克公司 改进的加环利定制剂
TWI265036B (en) * 2005-04-29 2006-11-01 Guo-Ming Huang Safety injector and method of operating the same
DE602006018460D1 (de) * 2005-05-18 2011-01-05 Gt Urological Llc Wirkstoffeluierung für implantierbare inkontinenzgeräte
CN1896729A (zh) 2005-07-15 2007-01-17 复旦大学附属中山医院 纳米药物自组装双稳态量子线阵列及其制备方法
US20070141148A1 (en) 2005-11-30 2007-06-21 Merz Pharma Gmbh & Co. Kgaa Neramexane MR matrix tablet
TW200819458A (en) * 2006-06-23 2008-05-01 Merz Pharma Gmbh & Co Kgaa Metabotropic glutamate receptor modulators
ATE532507T1 (de) * 2007-09-12 2011-11-15 Merz Pharma Gmbh & Co Kgaa Neramexane zur behandlung von subakuten tinnitus
TW201010691A (en) * 2008-06-12 2010-03-16 Merz Pharma Gmbh & Co Kgaa 1-amino-alkylcyclohexane derivatives for the treatment of sleep disorders
TW201006463A (en) * 2008-06-26 2010-02-16 Merz Pharma Gmbh & Co Kgaa Pharmaceutical compositions comprising aminocyclohexane derivatives
RU2011113733A (ru) * 2008-09-10 2012-10-20 Мерц Фарма Гмбх Унд Ко. Кгаа (De) Производные 1-амино-алкилциклогексана для лечения когнитивного нарушения при шуме в ушах
US20110294890A1 (en) * 2010-05-28 2011-12-01 Merz Pharma Gmbh & Co. Kgaa Neramexane for the treatment or prevention of inner ear disorders
JP6084931B2 (ja) * 2011-01-20 2017-02-22 メルツ ファーマ ゲゼルシャフト ミット ベシュレンクテル ハフツング ウント コンパニー コマンディト ゲゼルシャフト アウフ アクティーン ストレス又は急性聴力損失に関連する耳鳴の治療又は予防のためのネラメキサン

Also Published As

Publication number Publication date
JP2010539116A (ja) 2010-12-16
US20110077304A1 (en) 2011-03-31
SI2200600T1 (sl) 2012-03-30
RU2011137131A (ru) 2013-03-20
PL2200600T3 (pl) 2012-04-30
KR20100052557A (ko) 2010-05-19
JP5784188B2 (ja) 2015-09-24
MX2010002733A (es) 2010-04-09
EP2200598A1 (en) 2010-06-30
US9498450B2 (en) 2016-11-22
KR20100052558A (ko) 2010-05-19
HRP20120046T1 (hr) 2012-02-29
WO2009033651A1 (en) 2009-03-19
ES2562709T3 (es) 2016-03-07
JP5613053B2 (ja) 2014-10-22
AU2008298017A1 (en) 2009-03-19
ZA201001262B (en) 2011-07-27
EP2548552B1 (en) 2015-11-18
TW200918042A (en) 2009-05-01
EP2386299B1 (en) 2016-07-13
US8877814B2 (en) 2014-11-04
EP2548552A2 (en) 2013-01-23
AU2008298018C1 (en) 2012-08-16
DK2200600T3 (da) 2012-01-23
AU2008298016B2 (en) 2012-02-02
ZA201001261B (en) 2011-08-31
AR070025A1 (es) 2010-03-10
CN101795679A (zh) 2010-08-04
ATE532507T1 (de) 2011-11-15
ZA201001263B (en) 2011-07-27
JP5612473B2 (ja) 2014-10-22
CA2699213A1 (en) 2009-03-19
EP2386299A2 (en) 2011-11-16
MX2010002734A (es) 2010-04-01
US9468610B2 (en) 2016-10-18
EP2203163A1 (en) 2010-07-07
US20110086916A1 (en) 2011-04-14
WO2009033650A1 (en) 2009-03-19
US20100298441A1 (en) 2010-11-25
MX2010002736A (es) 2010-04-01
AU2008298015A1 (en) 2009-03-19
AU2008298018B2 (en) 2012-01-19
US20170027885A1 (en) 2017-02-02
EP2200599B1 (en) 2016-08-31
JP5563460B2 (ja) 2014-07-30
ES2510565T3 (es) 2014-10-21
ES2377253T3 (es) 2012-03-23
EP2200600B1 (en) 2011-11-09
KR20100052556A (ko) 2010-05-19
EP2200599A1 (en) 2010-06-30
PT2200600E (pt) 2012-02-17
CA2699210A1 (en) 2009-03-19
EP2203163B1 (en) 2014-08-27
AU2008298017B2 (en) 2012-03-01
JP2014221767A (ja) 2014-11-27
AR071728A1 (es) 2010-07-14
TW200927087A (en) 2009-07-01
TW200922544A (en) 2009-06-01
CN101835469A (zh) 2010-09-15
BRPI0816690A2 (pt) 2016-11-01
EP2200600A1 (en) 2010-06-30
CN101801365A (zh) 2010-08-11
WO2009033652A1 (en) 2009-03-19
US20150018425A1 (en) 2015-01-15
JP2010539118A (ja) 2010-12-16
JP5784189B2 (ja) 2015-09-24
WO2009033649A1 (en) 2009-03-19
MX2010002735A (es) 2010-04-01
AU2008298015B2 (en) 2012-03-22
ZA201001264B (en) 2011-07-27
JP2014221766A (ja) 2014-11-27
US20100298440A1 (en) 2010-11-25
AR070026A1 (es) 2010-03-10
JP2010539115A (ja) 2010-12-16
KR20100052559A (ko) 2010-05-19
CA2699209A1 (en) 2009-03-19
ES2604945T3 (es) 2017-03-10
CA2699207A1 (en) 2009-03-19
CN101801366A (zh) 2010-08-11
ES2596262T3 (es) 2017-01-05
JP5563461B2 (ja) 2014-07-30
JP2010539117A (ja) 2010-12-16
EP2548552A3 (en) 2013-10-16
EP2386299A3 (en) 2012-05-02
AU2008298016A1 (en) 2009-03-19
AU2008298018A1 (en) 2009-03-19

Similar Documents

Publication Publication Date Title
BRPI0807987A2 (pt) Terapia de combinação para tratamento de distúrbios imunes.
BRPI0921321A2 (pt) métodos para o tratamento de indwcções e tumores
ZA201001262B (en) Interval therapy for the treatment of tinnitus
BRPI0716844A2 (pt) Inidores de quinase úteis para o tratamento de doenças proliferativas
BRPI0821660A2 (pt) Combinações de agentes terapêuticos para tratamento de câncer
BRPI0908026A2 (pt) Métodos para o tratamento de doenças do intestino
HUE054495T2 (hu) Rák kezelésére szolgáló készítmény
BRPI0810082A2 (pt) 3-imidazolil-indóis para o tratamento de doenças proliferativas
BRPI0819241A2 (pt) Compostos derivados de amina para o tratamento de distúrbios e doenças oftálmicas
DK2154971T3 (da) Synergistisk farmaceutisk kombination til behandling af cancer
BRPI0919288A2 (pt) teriapia de combinação para tratamento de diabetes e condições relacionadas.
BRPI0922771A2 (pt) agentes indutores de apoptose seletivos para bcl-2 para o tratamento de câncer e doenças imunes
BRPI1013698A2 (pt) métodos para tratamento com o uso de terapia de combinação
PL2338519T3 (pl) Środek do leczenia zwłóknienia szpiku
DK2056842T3 (da) Modificeret galactosylceramid til behandling af cancerøse sygdomme
BRPI0813670A2 (pt) Compostos para tratamento
BRPI0911577A8 (pt) derivados espiro-indol para o tratamento de doenças parasíticas.
BRPI0815551A2 (pt) Tratamento através de hucbc de doença beta-amiloide
IL209336B (en) Compositions for treating hyperproliferative diseases and uses thereof
BRPI1009783A2 (pt) compostos para o tratamento de distúrbios metabólicos.
BRPI0818170A2 (pt) 5-cianotienopiridinas para o tratamento de tumores.
BRPI1007995A2 (pt) orto-aminoamidas para o tratamento de cãncer.
BRPI0906606A2 (pt) Tratamento terapêutico para condições do pulmão.
BR112012004836A2 (pt) pirazinilpiridinas úteis para o tratamento de doenças proliferativas
BRPI0912687A2 (pt) uso de bactéria probiótica para o tratamento de hiperhomocisteinaemia

Legal Events

Date Code Title Description
B15I Others concerning applications: loss of priority
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]
B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]